Posts
Hereditary Angioedema is a disease, which is the result of genetic
mutation, within the families with higher genetic activity. It is not
contagious to others. The cause of heredity is still unknown but it is believed
that the disease is related to the immunological mechanism. Hereditary
Angioedema is a chronic non-inflammatory disease that affects millions of
people around the world. Symptoms include persistent dryness of the skin, scalp
itching, inflammation, rash, severe skin peeling and cracking, bleeding and
hives, pain in the area where the skin is affected. As a part of the diagnosis,
a medical practitioner who is experienced in treating hereditary angioedema
must do a skin biopsy to find out the exact cause of allergic skin reaction.
Rising awareness regarding hereditary
angioedema is expected to drive growth of the global hereditary angioedema
market during the forecast period. Hereditary angioedema or also referred to as
HAE has received significant attention in the recent past as government and non-government
organizations across the globe are focused on increasing public awareness to
improve diagnosis and enhance the treatment. For instance, in April 2019, HAE
International (HAEi) organized an HAE global walk across various countries
including Argentina, Australia, New Zealand, Denmark, Finland, Malta, etc.
Thus, these factors are expected to drive growth of the global hereditary
angioedema market during the forecast period. Moreover, the prevalence of
hereditary angioedema is expected to boost the global hereditary angioedema
market growth over the forecast period. According to the National Institutes of
Health (NIH), hereditary angioedema is expected to affect 1 in 500,000 people
in the U.S., of which 85% of cases are expected to be Type I.
However, misdiagnosis of hereditary angioedema is expected to
hamper the global hereditary angioedema market growth over the forecast period.
Besides, continuous research and development activities in the field of orphan
drug development can present lucrative growth opportunities in the global
hereditary angioedema market in the near future. Among regions, North America
is expected to witness significant growth in the global hereditary angioedema
market during the forecast period. This is owing to the presence of robust
healthcare infrastructure and new product launches by market players across the
region. Moreover, Asia Pacific is expected to register a robust growth rate
over the forecast period, owing to rising patient awareness across the region.
Major companies involved in the global hereditary angioedema
market are BioCryst Pharmaceuticals, Inc., KalVista Pharmaceuticals, Inc.,
Ionis Pharmaceuticals, Inc., Adverum Biotechnologies, Inc., Pharming Group
N.V., Attune Pharmaceuticals, Inc., CSL Limited, and Shire plc.
For instance, in December 2020, BioCryst Pharmaceuticals, Inc.
received the U.S. Food and Drug Administration (FDA) approval for oral
once-daily ORLADEYO for prophylaxis to prevent hereditary angioedema (HAE).
No comments:
Post a Comment